^Olianas MC, Onali P (1999). "PD 102807, a novel muscarinic M4 receptor antagonist, discriminates between striatal and cortical muscarinic receptors coupled to cyclic AMP".Life Sciences.65(21): 2233–40.doi:10.1016/S0024-3205(99)00488-9.PMID10576595.
^Varoli L, Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Bedini A, Fazio N, Spampinato S (May 2008). "Diphenidol-related diamines as novel muscarinic M4 receptor antagonists".Bioorganic & Medicinal Chemistry Letters.18(9): 2972–6.doi:10.1016/j.bmcl.2008.03.061.PMID18395442.
^Böhme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD (July 2002). "Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors".Journal of Medicinal Chemistry.45(14): 3094–102.doi:10.1021/jm011116o.PMID12086495.
^Hogan K, Markos F (February 2007). "Muscarinic type 1 receptors mediate part of nitric oxide's vagal facilitatory effect in the isolated innervated rat right atrium".Nitric Oxide: Biology and Chemistry.16(1): 110–7.doi:10.1016/j.niox.2006.05.005.PMID16843016.
^Myslivecek J, Klein M, Novakova M, Ricny J (July 2008). "The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles".Naunyn-Schmiedeberg's Archives of Pharmacology.378(1): 103–16.doi:10.1007/s00210-008-0285-8.PMID18443764.
^Lau BK, Vaughan CW (November 2008). "Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray".Molecular Pharmacology.74(5): 1392–8.doi:10.1124/mol.108.045872.PMID18678620.